The goods and services tax (GST) council has announced sweeping reforms in the GST structure that promise to fundamentally transform the accessibility and affordability of healthcare services and insurance products across the nation. The 56th GST council meeting, chaired by Union minister of finance Nirmala Sitharaman, has delivered what industry experts are calling the most significant healthcare-focused tax reform since the implementation of GST, with changes set to take effect from 22 September 2025.
Complete Insurance Premium Tax Exemption
Perhaps the most transformative aspect of these reforms is the complete elimination of GST on insurance premiums. All individual health insurance policies, including family floater plans and senior citizen policies, along with their reinsurance services, will now be completely exempt from GST. Similarly, all individual life insurance policies, including term plans, unit-linked insurance plans (ULIPs), and endowment plans, as well as their reinsurance services, will attract nil GST. The council clarified that group insurance policies will continue to attract the existing 18% tax.
This represents a fundamental shift from the previous 18% GST that was levied on insurance premiums. For consumers, this means that a health insurance policy with an annual premium of Rs20,000 will no longer carry an additional Rs3,600 GST burden, providing immediate and tangible relief to policyholders across the country.
The insurance sector reform addresses one of the most significant barriers to insurance adoption in India. The elimination of the 18% tax burden is expected to make insurance policies substantially more affordable and accessible, particularly for first-time buyers and middle-income households who had previously found insurance premiums prohibitively expensive.
Landmark Healthcare Equipment Reforms
The healthcare sector has emerged as a primary beneficiary of these comprehensive tax reforms, with significant reductions in GST rates across multiple categories of medical equipment and supplies. The council has implemented a systematic approach to reduce the tax burden on essential healthcare products, recognising the critical role these items play in both preventive and curative healthcare delivery.
Medical apparatus and devices used for surgical, dental, veterinary, diagnostic, or analytical purposes will see their GST rates reduced from 18% to 5%. This substantial reduction covers a wide range of sophisticated medical equipment that forms the backbone of modern healthcare delivery, from diagnostic machines to surgical instruments used in operating theatres across the country.
Essential medical supplies, including wadding, gauze, bandages, diagnostic kits, reagents and glucometers, will benefit from a reduction in GST from 12% to 5%. These items represent the daily consumables that healthcare facilities rely upon for patient care and the reduced tax burden is expected to translate into lower costs for both healthcare-providers and patients.
The reform extends to corrective spectacles, which will now attract only 5% GST, reduced from the previous rates of 12% and 18% depending on the category. This change recognises vision correction as an essential healthcare need rather than a luxury item, making corrective eyewear more affordable for millions of Indians who require visual aids.
Life-saving Medicines Receive Complete Tax Exemption
In a move that will provide direct relief to patients battling critical illnesses, the GST council has completely eliminated taxes on life-saving medications. Thirty-three life-saving drugs used to treat critical conditions including cancer and rare diseases will now attract nil GST, reduced from the previous 12% rate.
Some of the high-cost cancer medicines that will now be tax-free under GST include:
• Daratumumab - used for multiple myeloma
• Teclistamab - for relapsed or refractory myeloma
• Amivantamab - lung cancer treatment
• Alectinib - for ALK-positive lung cancer
• Polatuzumab vedotin - for lymphoma
• Asciminib - for chronic myeloid leukemia
• Pegylated Liposomal Irinotecan - used in pancreatic cancer
A therapy costing Rs5 lakh earlier included Rs25,000 to Rs60,000 in GST outgo which will now be fully waived. For patients undergoing long-term treatment regimens, the cumulative savings could run much higher. The reform also means that insurance payouts will stretch further, as the tax component will no longer inflate bills, easing reimbursement and reducing out-of-pocket expenses.
This represents a complete elimination of the tax burden on these essential medications that often form the backbone of treatment for serious medical conditions.
Additionally, three other vital life-saving drugs have been moved from a 5% GST rate to complete exemption. These medications, specifically used in the treatment of cancer, rare diseases and severe chronic conditions, will now be available without any tax burden, reducing the financial stress on patients and families dealing with serious health challenges.
The broader pharmaceuticals sector also benefits from reduced taxation, with GST on all other drugs and medicines being reduced from 12% to 5%. This across-the-board reduction ensures that the affordability improvements extend beyond just life-saving medications to include the full spectrum of pharmaceutical products used in routine healthcare.
Understanding the Complex Economics of Input Tax Credits
While the elimination of GST on insurance premiums appears to offer straightforward savings, the actual economic impact involves considerations related to input tax credits (ITC).
ITC is a core feature of the current GST system, allowing businesses to offset taxes paid on inputs against taxes payable on outputs, preventing tax cascading. Eliminating ITC would mean businesses cannot claim credit for taxes paid on inputs, potentially increasing tax costs and affecting pricing and cash-flow.
Insurance companies currently operate within a framework where they collect 18% GST from policyholders while paying GST on operational activities, including agent commissions, marketing expenses, office rent, professional services, IT systems, claims processing and medical network services.
Under the existing system, insurers can adjust the tax they pay on business activities against the tax they collect from customers. With zero GST on premiums, insurers will lose this ability to claim ITC, fundamentally altering their cost structure.
Nilesh Sathe, a former member of the Insurance Regulatory and Development Authority of India (IRDAI), estimates this could result in about 3% revenue loss for new sales, though the major impact will be on existing policies where premium increases cannot be easily implemented.
The government has provided assurance that the benefits of these reforms will reach consumers. Finance minister Sitharaman confirmed that the decision was made after consultations with all stakeholders and emphasised the government's commitment to ensuring that consumers genuinely benefit from reduced costs.
Market Reality Check: Insurance Stocks Tumble Despite GST Relief
Shares of major insurance companies in India, including HDFC Life Insurance, SBI Life Insurance and Life Insurance Corporation of India (LIC), gave up significant early gains in trading on Thursday despite the GST Council's decision to exempt individual life and health insurance premiums from the 18% GST.
The announcement, made late on 3 September 2025, was initially met with optimism, as it promised to make insurance more affordable. However, concerns over the loss of ITC and the unchanged inverted duty structure led to a sharp reversal in stock prices.
Market Performance Analysis - Opening vs Current Prices:
Max Financial Services: Open Rs1,662.90, Current: Rs1,588.20 (-4.49%)
HDFC Life Insurance: Open Rs803.00, Current: Rs774.00 (-3.61%)
SBI Life Insurance: Open Rs1,890.00, Current: Rs1,812.00 (-4.13%)
PB Fintech Ltd: Open Rs1,900.00, Current: Rs1,895.00 (-0.26%)
ICICI Prudential: Open Rs640.00, Current: Rs608.40 (-4.94%)
The market reaction reveals a complex dynamic where the immediate benefits of GST exemption are being weighed against the longer-term revenue implications from loss of ITC.
Most major insurance stocks experienced declines ranging from 3.6% to 4.9%, with only PB Fintech showing minimal decline, possibly due to its intermediary business model being less directly impacted by the ITC loss.
Implementation Timeline and Practical Considerations
The revised GST rates across healthcare and insurance sectors will come into effect from 22 September 2025, strategically timed to coincide with the beginning of Navratri. This implementation date provides both industries adequate time to adjust their pricing structures, update their systems and prepare their distribution channels for the expected changes in demand patterns.
For healthcare providers, the reduced GST rates on medical equipment and supplies are expected to translate into lower operational costs, which can potentially be passed on to patients through reduced consultation fees, diagnostic charges and treatment costs. The standardisation of GST rates across different categories of healthcare products will also bring greater consistency to the taxation system, reducing compliance complexities for healthcare providers.
Insurance companies face the challenge of restructuring their pricing models to account for the loss of input tax credits while ensuring that the intended consumer benefits are realised. The regulatory framework requires that any changes to premium structures must be accompanied by policy modifications, meaning insurers may need to withdraw existing plans and relaunch new products with adjusted pricing, subject to regulatory approval.
Industry Response and Market Implications
The healthcare industry has responded enthusiastically to these reforms, recognising their potential to transform market dynamics and accessibility. Ameera Shah, president of NATHEALTH and executive chairperson of Metropolis Healthcare Ltd, described the measures as progressive reforms that acknowledge the critical role of preventive health and supporting medical technology in strengthening healthcare delivery.
The reforms are expected to enhance access to quality healthcare services, support early disease detection and bring greater consistency by standardising GST rates across preventive, curative and rehabilitative care. The reduction in costs is anticipated to make essential healthcare services and products more affordable for citizens across all economic segments.
Rajiv Nath from the Association of Indian Medical Device Industry (AiMeD) welcomed the tax cuts while highlighting the need for speedy refunds of accumulated GST to prevent inverted GST structures. The industry has assured its commitment to passing on the full benefits to consumers while requesting a transition period to adjust packaging and pricing without fear of profiteering accusations.
The pharmaceutical sector, represented by the Indian Pharmaceutical Alliance, has welcomed the government's decision to exempt life-saving and cancer medicines from GST. Secretary general Sudarshan Jain emphasised that these reforms will improve the accessibility of medicines, ensure wider availability across healthcare settings and contribute positively to the government's vision of affordable healthcare for all.
Addressing Implementation Challenges and Refund Mechanisms
The GST Council has directed the Central Board of Indirect Taxes and Customs (CBIC) to implement a revised refund mechanism to address concerns about inverted duty structures that may arise from these rate reductions. The new system will allow for 90% provisional refunds arising from an inverted duty structure based on data analysis and risk evaluation, similar to the risk-based refund model used for zero-rated supplies.
This mechanism is particularly important for the healthcare sector, where manufacturers and service providers may face situations where the GST on their inputs exceeds the GST on their outputs. The expedited refund process is designed to ensure that the benefits of reduced GST rates translate into actual cost savings rather than creating liquidity challenges for businesses.
For the medical device industry, Himanshu Baid, managing director of Poly Medicure Ltd, described the GST reduction as a transformative step that will directly benefit patients by lowering treatment costs, improving affordability and expanding access to essential medical technologies. The industry views this as strengthening India's healthcare system and advancing the vision of affordable healthcare for all.
Broader Economic and Social Implications
These comprehensive reforms represent more than mere tax adjustments; they constitute a strategic intervention designed to strengthen India's healthcare infrastructure and social security framework. By making both healthcare services and insurance protection more accessible, the government aims to create a more resilient healthcare ecosystem where individuals and families are better protected against medical emergencies and health uncertainties.
The decision aligns with broader economic objectives of increasing healthcare accessibility and insurance penetration rates. With lower barriers to entry, more Indians are likely to consider both insurance and preventive healthcare as viable components of their financial planning, potentially leading to improved health outcomes at both individual and societal levels.
The reforms are expected to have particularly significant impacts in rural and semi-urban areas, where cost sensitivity is especially high. Lower costs for medical equipment, medicines and insurance could open up entirely new market segments that were previously excluded from the formal healthcare system, contributing to broader financial inclusion and health security objectives.
Long-term Vision for Healthcare Accessibility
The comprehensive nature of these reforms reflects the government's commitment to using fiscal policy as a tool for social welfare enhancement. By simultaneously addressing healthcare equipment costs, medicine prices and insurance affordability, the policy creates a holistic approach to healthcare accessibility that addresses multiple barriers to healthcare access.
The reforms support the government's vision of ‘Insurance for All by 2047’ and contribute to building a more inclusive healthcare system. The elimination of tax barriers on essential healthcare components is expected to accelerate the adoption of both preventive care and financial protection mechanisms, creating a virtuous cycle of improved health outcomes and financial security.
Industry leaders across healthcare and insurance sectors have emphasised their commitment to ensuring that the benefits of these reforms reach end consumers. The combination of government oversight, industry commitment and market dynamics is expected to create conditions where the intended policy objectives of improved affordability and accessibility are genuinely achieved.
Future Outlook and Implementation Success Factors
The success of these landmark reforms will depend on effective implementation across multiple stakeholders, including healthcare providers, insurance companies, pharmaceutical manufacturers and medical device companies. The government's commitment to monitoring implementation and ensuring consumer benefit passage indicates ongoing regulatory oversight to prevent potential exploitation of the reforms.
The comprehensive GST reforms in healthcare and insurance represent a pivotal moment in India's journey toward universal healthcare accessibility and financial protection, with the potential to transform the lives of millions by making essential healthcare services and insurance coverage both accessible and affordable for a much broader segment of the population. The integration of healthcare equipment cost reductions with insurance premium eliminations creates a comprehensive approach to healthcare affordability that addresses the full spectrum of healthcare financial challenges faced by Indian families.
Also Read:
